Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

FSD Pharma Inc. - Class B Subordinate Voting Shares (NQ:HUGE)

0.0899 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FSD Pharma Inc. - Class B Subordinate Voting Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. 
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
Via Investor Brand Network
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference
Via Investor Brand Network
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors
Via Investor Brand Network
FSD Pharma Announces Changes to the Board of Directors
From FSD Pharma Inc.
Via Business Wire
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Multimillion-Dollar Claim Has Been Dismissed
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Dismissal of Claim by Former CEO
Via Investor Brand Network
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From FSD Pharma Inc.
Via Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Participation at H.C. Wainwright 24th Annual Global Investment Conference
Via Investor Brand Network
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available
From FSD Pharma Inc.
Via Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201
Via Investor Brand Network
Exposures Product Safety
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
From FSD Pharma Inc.
Via Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Report of Annual General Meeting of Shareholders
Via Investor Brand Network
FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates
From FSD Pharma Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
On Friday, 61 companies hit new 52-week lows. 
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits IND Application
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis Product Safety
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Files IND Application for Phase-2 Trial of FSD-PEA
Via Investor Brand Network
Exposures Product Safety
FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates
From FSD Pharma Inc.
Via Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs
Via Investor Brand Network
FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video
Via Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
FSD Pharma Closes CA$16.4M Sale Of Ontario Cannabis Processing Facility, Here's What's Next
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) has closed the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CA$16.4... 
Via Benzinga
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Announces Dismissal of Derivative Complaint
From FSD Pharma Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.